サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1597065

欧州の薬物動態サービス市場の将来予測 (2031年まで) - 地域別分析：薬剤の種類別、サービスの種類別、治療用途別、エンドユーザー別

Europe Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User

出版日
ページ情報
英文 87 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
欧州の薬物動態サービス市場の将来予測 (2031年まで) - 地域別分析：薬剤の種類別、サービスの種類別、治療用途別、エンドユーザー別
出版日: 2024年10月17日
発行: The Insight Partners
ページ情報: 英文 87 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の薬物動態サービス市場は、2023年に2億2,216万米ドルと評価され、2031年には3億8,738万米ドルに達すると予測され、2023年から2031年までのCAGRは7.2%と推定されます。

CROへの薬物動態サービスのアウトソーシングが欧州薬物動態サービス市場を牽引

CRO（医薬品開発業務受託機関）への薬物動態サービスのアウトソーシングは、医薬品メーカーやスポンサーにいくつかの利点を提供します。これらのサービスを選択することで、コスト効率よく業務を行うことができます。さらに、迅速なターンアラウンドタイムを達成すると同時に、柔軟な作業とコア業務への拡張性に集中することができます。アウトソーシングにより、製薬会社は能力開発、コスト削減、データ管理などの対策を実施しながら、製品の商業化に集中することができます。創薬プロセスは複雑であり、エラーや誤った結果があれば、多大なコストやプロセスの遅延につながります。CROは、薬物動態学などの専門知識を持つ経験豊富な科学者や研究者を雇用しています。そのため、CROは製薬会社に彼らの専門知識へのアクセスを提供することで、そのような熟練した人材の雇用や、人材育成のための追加トレーニングに投資する必要がなくなります。そのため、有望な新薬候補がありながらリソースが限られている小規模企業や、事業の多角化に取り組んでいる大企業は、組織化されたCROが提供する臨床研究サービスを選択しており、欧州の薬物動態サービス市場を強化しています。

欧州薬物動態サービス市場概要

欧州薬物動態サービス市場は、ドイツ、フランス、英国、スペイン、イタリア、その他欧州に区分されます。ドイツやイタリアなどの国々は、この地域の市場で大きな貢献者シェアを占めると予想され、フランス、英国、スペインなどの国々は、薬物動態サービスの成長機会を持つと思われます。欧州の薬物動態サービス市場は、新薬開発のための臨床試験数の増加や、薬物動態の変動を理解するためのin-vivoおよびin-vitroモデルの採用増加により、今後数年間で成長すると予想されます。

欧州薬物動態サービス市場の収益と2031年までの予測（単位：100万米ドル）

欧州薬物動態サービス市場セグメンテーション

欧州の薬物動態サービス市場は、薬剤の種類別、サービスの種類別、治療用途別、エンドユーザー別、国別に分類されます。

薬剤の種類別では、欧州の薬物動態サービス市場は低分子、高分子、ワクチンに区分されます。低分子セグメントは2023年に最大の市場シェアを占めました。

サービスの種類別では、欧州の薬物動態サービス市場は前臨床ADMEおよびヒト試験、PK/PD解析および報告、投与シミュレーション、リスク解析、その他に分類されます。2023年には、前臨床ADMEおよびヒト試験セグメントが最大の市場シェアを占めています。

治療用途別では、欧州の薬物動態サービス市場は、がん、感染症、神経疾患、自己免疫疾患、婦人科疾患、心血管疾患、呼吸器疾患、その他に区分されます。2023年には、がん領域が最大の市場シェアを占めています。

エンドユーザー別では、欧州の薬物動態サービス市場は製薬・バイオテクノロジー企業、CRO、その他に区分されます。2023年にはCROが最大の市場シェアを占めました。

国別では、欧州の薬物動態サービス市場はドイツ、フランス、英国、イタリア、スペイン、その他欧州に区分されます。2023年の欧州の薬物動態サービス市場シェアはフランスが独占しています。

Charles River Laboratories International Inc、Eurofins Scientific SE、Evotec SE、Certara Inc、Parexel International Corp、Thermo Fisher Scientific Inc、Allucent、PACIFIC BIOLABS、SGS SAなどが、欧州の薬物動態サービス市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 欧州の薬物動態サービス市場：主要な市場力学

  • 市場促進要因
    • 慢性疾患・感染症の有病率の上昇
    • 薬物動態研究への応用範囲の拡大
    • CROへの薬物動態サービスのアウトソーシング
  • 市場抑制要因
    • 新興国における薬物動態サービス業者のリーチの制約
  • 市場機会
    • 薬物動態のばらつきを理解するための生体内・生体外モデルの採用増加
  • 今後の動向
    • 薬物動態サービスにおけるビッグデータ解析の採用増加
  • 促進要因と阻害要因の影響

第5章 欧州の薬物動態サービス市場の分析

  • 欧州の薬物動態サービス市場の収益 (2021～2031年)

第6章 欧州の薬物動態サービス市場の分析：薬剤の種類別

  • 低分子
  • 大型分子
  • ワクチン

第7章 欧州の薬物動態サービス市場の分析：サービスの種類別

  • 前臨床ADMEおよびヒト試験
  • PK/PD分析とレポーティング
  • 投与シミュレーション
  • リスク分析
  • その他

第8章 欧州の薬物動態サービス市場の分析：治療用途別

  • がん領域
  • 感染症
  • 神経疾患
  • 自己免疫疾患
  • 婦人科疾患
  • 循環器疾患
  • 呼吸器疾患
  • その他

第9章 欧州の薬物動態サービス市場の分析：エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • CRO (医薬品開発業務受託機関)
  • その他

第10章 欧州の薬物動態サービス市場：国別分析

  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他

第11章 企業プロファイル

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA

第12章 付録

図表

List Of Tables

  • Table 1. Europe Pharmacokinetics Services Market Segmentation
  • Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 26. Glossary of Terms

List Of Figures

  • Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
  • Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
目次
Product Code: BMIRE00030902

The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.

Outsourcing of Pharmacokinetics Services to CROs Drives Europe Pharmacokinetics Services Market

Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.

Europe Pharmacokinetics Services Market Overview

The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.

Europe Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Europe Pharmacokinetics Services Market Segmentation

The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pharmacokinetics Services Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 4.2 Market Restraints
    • 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 4.4 Future Trend
    • 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Europe Analysis

  • 5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Europe Pharmacokinetics Services Market Analysis - by Drug Type

  • 6.1 Overview
  • 6.2 Small Molecule
    • 6.2.1 Overview
    • 6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Large Molecule
    • 6.3.1 Overview
    • 6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Vaccines
    • 6.4.1 Overview
    • 6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Pharmacokinetics Services Market Analysis - by Service Type

  • 7.1 Overview
  • 7.2 Pre-Clinical ADME and Human Studies
    • 7.2.1 Overview
    • 7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 PK/PD Analysis and Reporting
    • 7.3.1 Overview
    • 7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Dosing Simulations
    • 7.4.1 Overview
    • 7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Risk Analysis
    • 7.5.1 Overview
    • 7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Neurological Disorders
    • 8.3.1 Overview
    • 8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Autoimmune Diseases
    • 8.4.1 Overview
    • 8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Gynecological Disorders
    • 8.5.1 Overview
    • 8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Cardiovascular Diseases
    • 8.6.1 Overview
    • 8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Respiratory Disorders
    • 8.7.1 Overview
    • 8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Pharmacokinetics Services Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Contract Research Organization
    • 9.2.1 Overview
    • 9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Pharmacokinetics Services Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
      • 10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

  • 11.1 Charles River Laboratories International Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eurofins Scientific SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Evotec SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Certara Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
  • 11.5 Parexel International Corp
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Thermo Fisher Scientific Inc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Allucent
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 PACIFIC BIOLABS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 SGS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms for Pharmacokinetic Services Market